Frontiers in Pharmacology (Sep 2021)
Corrigendum: NLRP3 Overexpression Associated With Poor Prognosis and Presented as an Effective Therapeutic Target in Osteosarcoma
- Zhen Huang,
- Zhen Huang,
- Zhen Huang,
- Hui Chen,
- Shenglin Wang,
- Hongxiang Wei,
- Xinwen Wang,
- Rongkai Shen,
- Yunqing Wang,
- Rongjin Lin,
- Jianhua Lin,
- Jianhua Lin
Affiliations
- Zhen Huang
- Department of Rehabilitation, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
- Zhen Huang
- Department of Orthopedics, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
- Zhen Huang
- Fujian Orthopedics Research Institution, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
- Hui Chen
- Department of Nephrology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
- Shenglin Wang
- Fujian Orthopedics Research Institution, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
- Hongxiang Wei
- Fujian Orthopedics Research Institution, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
- Xinwen Wang
- Department of Orthopedics, The People’s Hospital of Jiangmen City, Southern Medical University, Jiangmen, China
- Rongkai Shen
- Fujian Orthopedics Research Institution, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
- Yunqing Wang
- Fujian Orthopedics Research Institution, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
- Rongjin Lin
- Department of Nursing, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
- Jianhua Lin
- Department of Orthopedics, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
- Jianhua Lin
- Fujian Orthopedics Research Institution, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
- DOI
- https://doi.org/10.3389/fphar.2021.753231
- Journal volume & issue
-
Vol. 12
Abstract
No abstracts available.Keywords